Friday, September 25, 2009

Medical News

Medical News


Fibrinolysis efficacy questioned for left-sided PVT in developing countries

Posted: 24 Sep 2009 05:00 PM PDT

Novel treatments are required for patients with left-sided prosthetic valve thrombosis in developing countries, say clinicians on finding fibrinolysis to be less effective for this indication than previously reported.

Pediatric stroke incidence ‘higher than thought’

Posted: 24 Sep 2009 05:00 PM PDT

The incidence of ischemic stroke in children is at least twice as high as previously thought, US researchers believe.

Symptom frequency needs to be considered when evaluating psoriasis severity

Posted: 24 Sep 2009 05:00 PM PDT

Researchers have called for the development of new scoring systems for evaluating psoriasis severity that incorporate the symptoms of the disease.

Presence of Hsp-27 protein at diagnosis indicates more aggressive prostate cancer

Posted: 24 Sep 2009 05:00 PM PDT

The presence of small heat shock protein-27 at prostate cancer diagnosis predicts a poor clinical outcome, say UK scientists.

Presence of Hsp-27 protein at diagnosis indicates more aggressive prostate cancer

Posted: 24 Sep 2009 05:00 PM PDT

The presence of small heat shock protein-27 at prostate cancer diagnosis predicts a poor clinical outcome, say UK scientists.

Daily mTOR inhibitor therapy effective for advanced breast cancer

Posted: 24 Sep 2009 05:00 PM PDT

Daily, but not weekly, treatment with the mammalian target of rapamycin inhibitor everolimus reveals single-agent antitumor activity in women with advanced breast cancer, Canadian researchers report.

New model for CVD risk prediction in Japanese effective

Posted: 24 Sep 2009 05:00 PM PDT

A new model for prediction of cardiovascular disease in Japanese individuals is effective at predicting risk, report researchers.

<i>APOA5</i> variant increases risk for high triglycerides in Type 2 diabetics

Posted: 24 Sep 2009 05:00 PM PDT

Hypertriglyceridemia associated with high levels of retinal binding protein 4 in individuals with Type 2 diabetes is enhanced in the presence of a variant of the apolipoprotein A5 gene, report researchers.

Colestilan improves glycemic control and LDL cholesterol in Type 2 diabetics

Posted: 24 Sep 2009 05:00 PM PDT

Results from a randomized trial of the bile acid sequestrant colestilan show that it is effective for improving glycated hemoglobin and reducing low-density lipoprotein cholesterol in Type 2 diabetics.

<i>APOA5</i> variant increases risk for high triglycerides in Type 2 diabetics

Posted: 24 Sep 2009 05:00 PM PDT

Hypertriglyceridemia associated with high levels of retinal binding protein 4 in individuals with Type 2 diabetes is enhanced in the presence of a variant of the apolipoprotein A5 gene, report researchers.

Incidence of Type 2 diabetes soaring in the Philippines

Posted: 24 Sep 2009 05:00 PM PDT

Revisiting a cohort from a national Filipino study population after 9 years reveals rapidly rising levels of Type 2 diabetes, researchers report.

Colestilan improves glycemic control and LDL cholesterol in Type 2 diabetics

Posted: 24 Sep 2009 05:00 PM PDT

Results from a randomized trial of the bile acid sequestrant colestilan show that it is effective for improving glycated hemoglobin and reducing low-density lipoprotein cholesterol in Type 2 diabetics.

Remote ischemic preconditioning reduces myocardial injury during CABG

Posted: 24 Sep 2009 05:00 PM PDT

Remote ischemic preconditioning reduces myocardial injury in patients undergoing coronary artery bypass graft surgery receiving cold-blood cardioplegia, a randomized study suggests.

Vitamin D deficiency exerts delayed effect on hypertension

Posted: 24 Sep 2009 05:00 PM PDT

Premenopausal women who have a deficiency in vitamin D face a 3-fold increased risk for developing systolic hypertension in later life compared with their peers who have normal levels, study findings show.

Daily mTOR inhibitor therapy effective for advanced breast cancer

Posted: 24 Sep 2009 05:00 PM PDT

Daily, but not weekly, treatment with the mammalian target of rapamycin inhibitor everolimus reveals single-agent antitumor activity in women with advanced breast cancer, Canadian researchers report.

No comments:

Post a Comment